Galectin Therapeutics Completes Enrollment Of Second Cohort Of Phase 1 Trial Of GR-MD-02 For NASH (Fatty Liver Disease) With Advanced Fibrosis
4/23/2014 9:21:44 AM
NORCROSS, Ga., April 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that all eight (8) patients have received their first infusion in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis. Patients in cohort 2 were successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. The clinical trial protocol specifies that eight patients are included in cohort 2; however, an additional two patients may be enrolled to ensure the requisite number of eight patients complete the 63-day protocol in the second cohort.
Help employers find you! Check out all the jobs and post your resume.
comments powered by